Cannabics
Pharmaceuticals has announced it has received Government Certification from the
Ministry of Health in Israel to establish an advanced R&D laboratory
dedicated to medical research in the area of cannabinoid science.
Cannabics
Pharmaceuticals’ goal is to be one of the first companies in the world to
commercialize indication specific and clinically tested cannabis-based medical
products. Running in concert with this goal, CNBX is in advanced preparations
for the roll out of a series of controlled clinical studies in leading medical
centers in Israel where the company’s R&D division is located.
The
company’s new state of the art laboratory is designed to use novel technologies
to develop innovative cannabinoid based therapies for various disabling
ailments.
CEO Dr.
Zohar Koren noted, “The exciting scientific field of cannabinoid research has
been largely neglected throughout most of the 20th century due to a total ban
on this field of research. Thus, the available scientific knowledge regarding
active cannabinoids and their mechanisms of action in various disease pathways
is dramatically lacking in comparison to other therapeutic fields. There is a
huge space of uncharted territory to explore with regards to the potential
therapeutic roles of this class of compounds for diverse indications.”
The
company is especially interested in the development of cannabinoid-based
anti-Cancer therapies.
“The
unique properties of active cannabinoids as tumor cell proliferation inhibitors
and apoptosis inducers has been known for decades, however this field has never
received the appropriate scientific attention it deserves as a potential source
for anti-cancer therapies,” commented Dr. Eyal Ballan, Chief Technology
Officer. “Our new and expansive laboratory will enable us to perform our
advanced research program in this field.”
Cannabics
Pharmaceuticals, Inc. is a drug development company whose efforts are focused
on the development and commercialization of advanced drugs, food supplements,
therapies and administration routes based on the wide range of active
ingredients found in diverse and unique strains of the Cannabis plant.
Cannabics’ core product is CANNABICS SR — an IP pending medical cannabis
capsule used with cancer patients as a palliative care treatment. In
observational studies, the company’s proprietary SR technology has shown the
ability to provide 10-12 hours of steady state beneficial therapeutic effects
profile. This allows for a once-per-day, oral dosing regimen of medical
cannabis for patients. CNBX is currently preparing to launch its line of SR
products in the US and EU markets under existing medical cannabis regulatory
pathways where eligible.
For more
information on the company, visit www.cannabics.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign up
for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see
disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment